Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CTLA-4/PD-1 bispecific antibody plus chemotherapy in second-line advanced esophageal squamous cell carcinoma
ChiCTR2600116490Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Jan 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoint: Objective Response Rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600116490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116490.